What Is 2-methoxyestradiol disulfamate

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 2-Methoxyestradiol disulfamate (2-MeO-E2 disulfamate) is an experimental anticancer agent derived from a natural estrogen metabolite. It combines 2-methoxyestradiol with a disulfamate group to enhance metabolic stability and antitumor activity, with research ongoing since the early 2000s.

Key Facts

2-Methoxyestradiol disulfamate is a synthetic derivative of 2-methoxyestradiol (2-ME), first studied in the early 2000s
It has a molecular weight of approximately 478.6 g/mol and improved metabolic stability over its parent compound
The compound inhibits tubulin polymerization, disrupting mitosis in cancer cells
Preclinical studies show activity against breast, prostate, and ovarian cancer cell lines
It is not FDA-approved and remains in investigational stages

Overview

2-Methoxyestradiol disulfamate is a synthetic analog of 2-methoxyestradiol (2-ME), a naturally occurring metabolite of estradiol. While 2-ME exhibits antiangiogenic and antiproliferative properties, its rapid metabolism limits clinical utility—prompting the development of more stable derivatives like 2-MeO-E2 disulfamate.

This compound was designed to overcome pharmacokinetic limitations by incorporating a disulfamate functional group, which enhances metabolic resistance and prolongs half-life. Research has primarily focused on its potential as a microtubule-disrupting agent in oncology, particularly in hormone-sensitive cancers.

Chemical modification: The addition of a disulfamate group to 2-methoxyestradiol significantly increases metabolic stability, reducing rapid hepatic breakdown seen in the parent compound.
Anticancer mechanism: It disrupts microtubule dynamics by inhibiting tubulin polymerization, leading to G2/M phase cell cycle arrest in proliferating tumor cells.
Targeted cancers: Preclinical models show efficacy against breast cancer (MCF-7), prostate cancer (PC-3), and ovarian cancer (SKOV-3) cell lines.
Improved bioavailability: Compared to 2-ME, the disulfamate derivative demonstrates 2.5-fold higher plasma half-life in rodent models, enhancing therapeutic potential.
Development timeline: First synthesized and tested in early 2000s by researchers aiming to optimize estrogen-based anticancer agents with reduced hormonal activity.

How It Works

The biological activity of 2-methoxyestradiol disulfamate stems from its ability to interfere with key cellular processes in cancer cells, particularly those involving cytoskeletal integrity and angiogenesis. Its design leverages structural changes to boost potency and pharmacokinetics.

Microtubule inhibition:Disrupts tubulin assembly by binding at the colchicine site, preventing proper mitotic spindle formation and triggering apoptosis in rapidly dividing cells.
Antiangiogenic effect: Suppresses VEGF expression and endothelial cell proliferation, reducing tumor blood supply and limiting metastatic potential in xenograft models.
Receptor-independent action: Unlike natural estrogens, it exhibits minimal affinity for estrogen receptors (ERα/ERβ), reducing risk of hormonal side effects.
Metabolic resistance: The disulfamate group shields the molecule from glucuronidation and sulfation, major inactivation pathways for 2-methoxyestradiol.
ROS induction: Increases intracellular reactive oxygen species (ROS) levels in cancer cells, contributing to DNA damage and mitochondrial dysfunction.
HDAC inhibition: Some studies suggest weak histone deacetylase (HDAC) inhibition, potentially altering gene expression in tumor cells.

Comparison at a Glance

The following table compares 2-methoxyestradiol disulfamate with its parent compound and a standard chemotherapeutic agent:

Property	2-Methoxyestradiol	2-MeO-E2 Disulfamate	Paclitaxel
Half-life (rats)	~30 minutes	~75 minutes	~4 hours
Tubulin inhibition	Moderate	Strong	Very strong
Estrogenic activity	Low	Negligible	None
Oral bioavailability	Poor	Moderate	Low (oral)
Clinical status	Phase II (discontinued)	Preclinical	Approved

This comparison highlights the pharmacological trade-offs between natural metabolites, synthetic derivatives, and established drugs. While 2-MeO-E2 disulfamate improves on the parent compound’s limitations, it has not advanced to clinical trials, unlike paclitaxel, which remains a cornerstone of chemotherapy.

Why It Matters

Though still experimental, 2-methoxyestradiol disulfamate represents an innovative approach to repurposing endogenous molecules for cancer therapy. Its development reflects broader trends in medicinal chemistry: optimizing natural compounds for enhanced efficacy and safety.

Novel drug design: Demonstrates how chemical derivatization can improve the pharmacokinetic profile of biologically active but unstable natural compounds.
Targeted therapy: Offers potential for hormone-independent anticancer effects, making it relevant for ER-negative tumors resistant to conventional hormonal treatments.
Combination potential: May synergize with existing chemotherapeutics like doxorubicin or cisplatin by targeting complementary pathways.
Reduced toxicity: Early studies suggest lower neurotoxicity compared to taxanes, which commonly cause peripheral neuropathy.
Patent activity: Multiple patents filed between 2003–2008 by academic and pharmaceutical groups indicate sustained interest in disulfamate-modified steroids.
Research catalyst: Spurred development of other non-hormonal estrogen analogs now under investigation for oncology and neurodegenerative diseases.

While not yet a clinical reality, 2-methoxyestradiol disulfamate exemplifies how rational drug design can breathe new life into overlooked biological pathways, paving the way for next-generation anticancer agents.